Gena Wang, an analyst from Barclays, maintained the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated price ...

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price ...

Those around that level are, disproportionately, relatively small and risky companies whose prospects don't look all that ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

As we start looking to the year ahead, the pharma industry is gearing up for a slate of new drug launches and U.S. Food and ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on multiple kidney diseases in its pipeline ...

The annual Santa Barbara Great Strides walk is a step around the corner and participating teams have already entered the race ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

On that note, let's dive in and investigate how the bull thesis for buying Vertex stock just got even stronger. Read More: ...

On Wednesday, Vertex Pharmaceuticals Incorporated (VRTX) stock saw a decline, ending the day at $470.05 which represents a decrease of $-4.86 or -1.02% from the prior close of $474.91. The stock ...

Nineteen companies are receiving $21.4 million total in tax incentive awards to create 1,155 new life sciences jobs in ...

The projected market expansion presents a unique opportunity for stakeholders to invest in and prioritize the development of ...